Intellia Therapeutics

204 articles about Intellia Therapeutics

• Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

  5/4/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

• Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

  5/1/2023

  Intellia Therapeutics, Inc. today released its 2023 Corporate Responsibility report.

• Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

  4/27/2023

  Intellia Therapeutics, Inc. will present its first quarter 2023 financial results and operational highlights in a conference call on May 4, 2023, at 8 a.m. ET.

• Intellia Therapeutics Names Bill Chase to its Board of Directors

  4/17/2023

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the appointment of Bill Chase, MBA, to its board of directors.

• 

  Gene Editing Therapeutics Could Hit the Market in 2023

  4/10/2023

  Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.
• 

  Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach

  4/4/2023

  With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases with an eye toward broader patient populations.

• Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

  3/21/2023

  Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).

• Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002

  3/2/2023

  Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).

• 

  Novartis Drops SCD Gene Therapy Program with Intellia

  2/23/2023

  Novartis has abandoned its ex vivo sickle cell disease program developed using Intellia Therapeutics’ CRISPR gene editing platform, Intellia announced Thursday.

• Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

  2/23/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2022.

• Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

  2/16/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET.

• Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

  1/11/2023

  Intellia Therapeutics, Inc. today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE).

• 

  Intellia Pushes NTLA-2001 Gene Editing Therapy to the Fore of Near-Term Priorities

  1/6/2023

  Intellia Therapeutics released its strategic priorities for 2023-2024 Thursday, with a heavy emphasis on advancing its lead asset NTLA-2001 as a potential functional cure therapy for ATTR amyloidosis. 

• Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

  1/5/2023

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced its strategic priorities for the upcoming two years as the Company enters its next phase of pipeline execution and platform innovation.

• Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - December 01, 2022

  12/1/2022

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share.

• Intellia Therapeutics Announces Proposed Public Offering of Common Stock - November 30, 2022

  11/30/2022

  Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced that it has commenced an underwritten public offering of $250 million of shares of its common stock.

• 

  Best Places to Work in Biopharma 2023 Report Reveals Most Sought-After Employers

  11/15/2022

  BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.

• Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

  11/12/2022

  Intellia Therapeutics, Inc. announced updated data from an ongoing Phase 1/2 clinical study of NTLA-2002 for the treatment of hereditary angioedema.

• Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the AHA Scientific Sessions 2022

  11/5/2022

  Intellia Therapeutics, Inc. presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin amyloidosis in collaboration with Regeneron Pharmaceuticals.

• Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

  11/3/2022

  Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2022.